source
- Aurora Therapeutics halts lead CRISPR program and cuts staffAurora Therapeutics, founded as the first company dedicated to developing custom CRISPR-based gene-editing medicines, announced a major restructuring. The firm said it is laying off several employ…
- BMS terminates Cellares partnership after cell therapy platform fails to meet Breyanzi production needs, prompting layoffsBristol Myers Squibb has ended its collaboration with manufacturing specialist Cellares after the Cell Shuttle system could not satisfy the requirements for producing the approved CAR‑T therapy Bre…